Cancer researchers have demonstrated a method to reprogram tumour cells into benign cells in what could be a dramatic breakthrough in the fight against the disease.
Scientists warn the method has only been trialled ‘in vitro’, and has not been tested on live human patients. But the hope is the technique may lead to a treatment for different cancers far less destructive than chemotherapy.
Cancer cells are essentially the same as normal cells, but instead of stopping the process of division during replication, they continue to divide. The result is a tumour. The instruction to stop dividing is usually controlled by microRNAs, small but critical biological markers within the cells, but something happens inside cancerous cells which stops that process.
The team at the Mayo Clinic in Florida found that by injecting human breast and bladder cancer cells with PLEKHA7 — the protein thought to stop cells dividing when added in the right quantities — they could transform cancer cells into benign cells. The insight into the role of PLEKHA7 helped the team understand how the behaviour of proteins E-cadherin and p120 catenin, which are critical for holding normal tissue together while also powering cancer division, could be regulated.
“We should be able to re-establish the brakes and restore normal cell function,” professor Panos Anastasiadis, of the Department for Cancer Biology at Mayo told The Telegraph. “Initial experiments in some aggressive types of cancer are indeed very promising.”
The study, published in Nature Cell Biology, is in theory a dramatic discovery, and if applicable in human trials would give doctors the ability to tell tumours to stop growing entirely.
“The study brings together two so-far unrelated research fields — cell-to-cell adhesion and miRNA biology — to resolve a long-standing problem about the role of adhesion proteins in cell behavior that was baffling scientists,” lead author Antonis Kourtidis said in a press statement “Most significantly, it uncovers a new strategy for cancer therapy.”
The Latest on: Reprogram tumour cells
[google_news title=”” keyword=”reprogram tumour cells” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Reprogram tumour cells
- This week in clinical trials: 29th January to 2nd Februaryon February 22, 2024 at 10:37 pm
Read on further for ongoing weekly news from studies across the globe. During the week of 29 th January to 2 nd February: Vidac announced positive interim results from Ph2a of VDA-1102 in Mycosis ...
- CAR-T therapy for multiple sclerosis enters US trials for first timeon February 21, 2024 at 4:00 pm
Hopes are high that engineered immune cells, which are already in use to treat blood cancer, will halt the progression of a degenerative autoimmune disorder.
- How the additives in your vaccines rev up your immune systemon February 21, 2024 at 12:00 pm
Additives like aluminum in vaccines can amp up their effectiveness, creating just the right balance of inflammation to prevent disease.
- The Unstoppable Momentum of Outdated Science: 2024 Updateon February 20, 2024 at 8:18 am
Occasionally, I’ll revisit some old posts to provide updates and also to introduce the many new subscribers at THB to things they may have missed. The original 2020 post that I revisit today — The ...
- Unveiling the role of CD24-Siglec10 axis in tumor immune evasionon February 19, 2024 at 4:00 pm
thus blocking the phagocytosis of tumor cells by macrophages and triggering tumor immune escape. Blocking the CD24-Siglec10 axis to reprogram the tumor immune microenvironment is a current research ...
- Could a single shot heal heart disease?on February 19, 2024 at 8:28 am
Multiple research teams at Penn Medicine are continuing to advance the science to develop new treatments for heart disease that could work with just one shot.
- Small molecules that switch up cell development could transform medicineon February 19, 2024 at 12:57 am
Turning mature somatic cells back into flexible stem cells using small molecules could revolutionise medicine, especially for regeneration and cancer. Philip Ball reports ...
- Astellas’s CAR Tech Deals Speed Up Its Pursuit of In Vivo Cancer Cell Therapieson February 16, 2024 at 9:58 am
Astellas Pharma is working with Kelonia Therapeutics, a startup that develops in vivo CAR T-therapies with technology that precisely delivers genetic cargo to cells. The collaboration combines this ...
- Smoking’s effects on the immune system can last years, study findson February 14, 2024 at 9:59 am
Smoking tobacco is so harmful to the body that it changes a person’s immune system, leaving them vulnerable to more disease and infection even years after they’ve quit, a new study found.
- Researchers identify promising therapeutic approach for patients with metastatic pancreatic canceron February 14, 2024 at 1:00 am
Lead author of the study, Professor Michael Schmid said: “In pancreatic cancer, malignant tumour cells often spread to the liver. Our data show that the generation of a supportive metastatic ‘niche’ ...
via Bing News